ReviewDepression and anxiety2011
Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.
Review in Depression and anxiety, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 28 citations in OpenAlex.
- Fentanyl Research: Key to Fighting the Opioid Crisis.Journal of clinical medicine · 2025Article
- Mu opioid receptors on hippocampal GABAergic interneurons are critical for the antidepressant effects of tianeptine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Modeling anorexia nervosa: transcriptional insights from human iPSC-derived neurons.Translational psychiatry · 2017Article
- Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review.Current neuropharmacology · 2015Review
- Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder.Current neuropharmacology · 2015Review
- Endocrinology and physiology of pseudocyesis.Reproductive biology and endocrinology : RB&E · 2013Review
- Opioid receptors: distinct roles in mood disorders.Trends in neurosciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
A better understanding of the neurobiology of mood disorders, informed by preclinical research and bi-directionally translated to clinical research, is critical for the future development of new and effective treatments. Recently, diverse new targets/compounds have been specifically tested in preclinical models and in proof-of-concept studies, with potential relevance as treatments for mood disorders. Most of the evidence comes from case reports, case series, or controlled proof-of-concept studies, some with small sample sizes. These include (1) the opioid neuropeptide system, (2) the purinergic system, (3) the glutamatergic system, (4) the tachykinin neuropeptide system, (5) the cholinergic system (muscarinic system), and (6) intracellular signaling pathways. These targets may be of substantial interest in defining future directions in drug development, as well as in developing the next generation of therapeutic agents for the treatment of mood disorders. Overall, further study of these and similar drugs may lead to a better understanding of relevant and clinically useful drug targets in the treatment of these devastating illnesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.